14 Nov 2008

TIBCO Spotfire (Research Instrument): Informed Decision Making in High Content Data Analysis
Thomas J. Murphy
Ph.D., Chief Scientific Officer, Life Sciences, Research Instruments Pte Ltd

TIBCO Spotfire DecisionSite® software is a highly configurable guided analytic application designed to enhance and accelerate decision-making. Typical applications include data-mining for microarray experiments and other high throughput screening. Its dynamic visualization engine, unified information access and role-configurable analytics combine to provide a rich environment for the integrated analysis of multiple data sets. By linking decision-making professionals, analytic information and key business processes at a single point of analysis, DecisionSite® helps business professionals make smarter decisions faster.

Research Instruments is the distributor for TIBCO Spotfire data analysis software in Singapore and Malaysia.

Do RSVP with Ms Guat Kheng TAN at email: gk.tan@ri.com.sg before 30 October 2008!

Speaker’s biography:

Dr Thomas Murphy currently holds the position of Chief Scientific Officer (Life Sciences) with Research Instruments Pte Ltd. Before relocating to Singapore, Dr Murphy was a scientific consultant with Thermo Fisher Scientific (formerly Dharmacon) when he educated and advised fellow scientists on advancements being made in the field of RNA interference. He is a cell biologist with over 10 years’ experience in molecular cell biology and target identification and validation. His particular research interests include biological imaging, cell signaling, and angiogenesis. Prior to Thermo Fisher Scientific, he worked at the Novartis Institute for Functional Genomics (GNF) in San Diego, where he was responsible for conceiving and implementing siRNA-based genomic screens against inflammatory and oncology pathways. He received his B.A. in Biology from Occidental College, followed by his Ph.D. from the Molecular Biology Institute at UC Los Angeles. He has also held research positions at UC San Francisco and Amgen Inc.

For more details, please contact Ms Guat Kheng TAN.